title: Rationale and design of the virological response and ribavirin dosage (VIRID) study in hepatitis.
authors.forename: J F
authors.initials: JF
authors.lastname: Bergmann
authors.forename: S
authors.initials: S
authors.lastname: Slavenburg
authors.forename: R
authors.initials: R
authors.lastname: Roomer
authors.forename: R J
authors.initials: RJ
authors.lastname: de Knegt
authors.forename: J P H
authors.initials: JP
authors.lastname: Drenth
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D006526:Hepatitis C / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009426:Netherlands; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin